Can Stem Cell Transplants Help with Multiple Sclerosis? What AHSCT Trials Show

Autologous hematopoietic stem cell transplantation (AHSCT) uses a patient's own blood-forming stem cells to rebuild the immune system after immunoablative chemotherapy wipes out the dysfunctional immune cells driving multiple sclerosis. For a specific, carefully defined group of patients — those with active, inflammatory relapsing-remitting MS that keeps breaking through standard drug therapy — randomized trial data now show disability and relapse outcomes that outperform continued disease-modifying therapy by a wide margin. This article walks through what the evidence actually shows, why patient selection determines nearly everything about whether AHSCT helps or harms, what the real risks are, and where the treatment currently stands with regulators and insurers in 2026.

What AHSCT Actually Does

AHSCT is not a stem cell "infusion" in the sense many wellness clinics imply. The procedure has three distinct phases. First, a patient's own hematopoietic (blood-forming) stem cells are mobilized out of the bone marrow and into the bloodstream using medication, then collected by apheresis and frozen. Second, the patient receives a course of immunoablative or myeloablative chemotherapy — regimens built around drugs like cyclophosphamide and antithymocyte globulin, sometimes with total body irradiation in older protocols — that deliberately destroys the existing immune system, including the autoreactive T and B cells believed to drive MS relapses. Third, the patient's own previously banked stem cells are reinfused, repopulating the bone marrow and allowing a new immune system to develop from scratch. The theory, and increasingly the demonstrated result, is that the "rebooted" immune system loses the autoreactivity that was attacking the central nervous system, halting new inflammatory disease activity.

What the Trial Evidence Actually Shows

The strongest evidence comes from the MIST trial (Burt et al., JAMA, 2019), a randomized controlled trial of 110 patients with relapsing MS who had experienced two or more relapses in the prior year despite disease-modifying therapy. Participants were randomized to AHSCT or to continued/switched conventional therapy. The results were striking: at one year, disability progression occurred in just 3 of 52 AHSCT patients compared with 34 of 51 patients on standard therapy. Over the full follow-up period (mean 2.8 years), the AHSCT group's average EDSS disability score actually improved, from 3.38 to 2.36, while the drug-therapy group's score worsened, from 3.31 to 3.98. No deaths occurred in either study arm.

That result has held up in follow-up cohorts rather than fading with time. A long-term Norwegian cohort (Kvistad et al., Multiple Sclerosis Journal, 2024) followed 29 patients with aggressive relapsing-remitting MS for a mean of nearly six years post-transplant: 69% remained free of any disease activity (NEDA-3), 90% were free of disability progression, and more than a third showed sustained, meaningful disability improvement. Full-time employment among participants rose from 3% before transplant to 52% at five years — a striking real-world marker of restored function. The 2025 ECTRIMS/EBMT consensus statement (Muraro et al., Nature Reviews Neurology) pooled outcomes across multiple contemporary cohorts and reported progression-free survival in the range of 73–100% and relapse-free survival around 81% over follow-up periods of two to ten years, with several comparative studies finding AHSCT outperforming high-efficacy drugs like alemtuzumab on relapse suppression and MRI activity. For the right patient, in other words, this is not a marginal or speculative benefit — it is trial-grade evidence of a treatment effect larger than what most currently approved disease-modifying therapies achieve.

Why Patient Selection Is the Whole Story

That evidence comes with an essential asterisk: it applies almost entirely to relapsing-remitting MS with ongoing inflammatory activity — recent relapses, active or new lesions on MRI, disease breaking through treatment — in patients who are relatively young, have a shorter disease duration, and remain ambulatory. Cleveland Clinic's transplant program describes the ideal candidate as "young (approximately 55 years or less), with relatively recent disease onset (approximately 10 years or less), still ambulatory, with highly active MS with recent clinical relapses or MRI lesion activity, and continued disease activity despite treatment with approved DMTs." The ECTRIMS/EBMT consensus statement is explicit that AHSCT is not recommended for primary progressive MS, and evidence for secondary progressive MS without ongoing inflammatory activity is limited at best. The biological logic is straightforward: AHSCT works by eliminating an overactive inflammatory immune response, so it has little to offer patients whose disability is driven mainly by neurodegeneration rather than active inflammation. Applying AHSCT outside these criteria is where outcomes data thins out and risk-benefit calculations shift unfavorably.

The Real Risks

AHSCT is a serious medical procedure, not an outpatient infusion, and that reality shouldn't be softened. The conditioning chemotherapy leaves patients with a period of profound immunosuppression, requiring hospitalization and carrying real infection risk during immune recovery. Historically, treatment-related mortality was a genuine concern: earlier EBMT registry data cited mortality around 3.6% with older, more intensive protocols. Patient selection, gentler non-myeloablative conditioning regimens, and greater center experience have driven that figure down substantially — Cleveland Clinic and recent EBMT data now put treatment-related mortality at roughly 0.2–0.3% for procedures performed at experienced centers after 2012. That is a dramatic improvement, but it is not zero, and outcomes remain closely tied to which center performs the procedure and how rigorously it screens candidates. Other risks are more common and less dramatic but still significant: autoimmune thyroid disease affects a meaningful minority of patients post-transplant (17% in the Norwegian cohort), and fertility impact is substantial — 62% of women in that same cohort showed signs of persisting ovarian failure. Patients considering AHSCT should discuss fertility preservation before conditioning begins.

Regulatory Status and Access

AHSCT is not FDA-approved as a treatment for MS. In the United States it is generally accessed either through a clinical trial — most notably the NIH-funded BEAT-MS trial comparing AHSCT directly against the best available high-efficacy drug therapies — or off-label at a small number of experienced transplant centers, an option typically reserved for patients who don't qualify for or can't access a trial. Cleveland Clinic states its priority is enrolling eligible patients in BEAT-MS rather than performing AHSCT outside a study framework. In the UK, NHS England funds AHSCT for eligible patients (generally those with an EDSS of 5.5 or lower and highly active relapsing disease) as part of a health-system pathway rather than a drug approval, and the ongoing StarMS trial there is comparing it head-to-head with modern high-efficacy DMTs, with results expected around 2027. Because it lacks MS-specific FDA approval, most US insurers won't cover AHSCT for MS outside a trial, and out-of-pocket cost for the procedure has been estimated at roughly $150,000, which is part of why unregulated clinics abroad marketing "stem cell treatment for MS" should be approached with particular skepticism — the rigor of patient selection and conditioning protocol is what makes the difference between the outcomes described above and a much riskier, unmonitored procedure.

Bottom Line

If you have relapsing-remitting MS with recent relapses or active MRI lesions despite treatment, AHSCT is worth a serious, informed conversation with a neurologist at a center with real transplant experience — the trial evidence for that specific situation is genuinely strong. Ask directly about your candidacy criteria (age, disease duration, inflammatory activity versus pure progression), the center's transplant-related mortality and complication rates, whether you'd qualify for a trial like BEAT-MS rather than paying out of pocket, and what fertility preservation options you have before conditioning starts. AHSCT is not an FDA-approved MS treatment, it is not appropriate for progressive MS without inflammatory activity, and it carries real risks that deserve as much weight as its real benefits — both should be part of the same conversation with your care team.